Welcome to our dedicated page for Emergent Biosolutions news (Ticker: EBS), a resource for investors and traders seeking the latest updates and insights on Emergent Biosolutions stock.
Emergent BioSolutions Inc (NYSE: EBS) is a leader in developing medical countermeasures for public health threats, with a focus on biodefense and emergency response solutions. This page provides investors and stakeholders with centralized access to official press releases, regulatory updates, and strategic developments from the life sciences innovator.
Discover timely updates on key initiatives including NARCAN distribution, government contract awards, and advancements in vaccine manufacturing. Our curated news collection covers earnings reports, partnership announcements, and progress on treatments addressing biological threats like anthrax and smallpox.
Stay informed about Emergent's role in global health security through updates on FDA submissions, manufacturing facility expansions, and collaborations with agencies like BARDA. Content is organized chronologically for easy tracking of operational milestones and financial performance.
Bookmark this page for direct access to verified corporate communications and analysis of how EBS navigates complex regulatory environments while maintaining its position as a critical partner in national preparedness programs.
Emergent BioSolutions (NYSE: EBS) is expanding access to NARCAN® Nasal Spray, the first FDA-approved over-the-counter 4 mg naloxone product for opioid overdose emergency treatment. The initiative comes as opioid overdose deaths show their first decline in five years nationwide.
The company is launching two key partnerships:
- Collaboration with NYC Building & Construction Industry Safety Fund to implement HOPE/LIVES program, providing training and emergency kits with two doses of NARCAN® to construction workers, who face higher opioid prescription rates and fatal overdose risks
- Partnership with Pathway Healthcare to supply NARCAN® Nasal Spray across their Mississippi locations, enhancing accessibility in addiction treatment and mental health facilities
These initiatives aim to increase opioid emergency preparedness and reduce barriers to access, while providing education on overdose recognition and proper administration of the life-saving medication.
Emergent BioSolutions (NYSE: EBS) has announced a strategic investment agreement with Rocketvax , a Swiss next-generation vaccine company. The partnership includes Emergent leading U.S. manufacturing and commercialization for four of Rocketvax's pipeline candidates targeting infectious diseases, cancer, and autoimmune disorders.
One of Rocketvax's leading candidates is a live-attenuated nasal spray SARS-CoV-2 vaccine, which has shown superior efficacy compared to mRNA COVID-19 vaccines in animal studies. Rocketvax has already secured a letter of intent with the NIH under Project NextGen initiative for clinical trials of their proprietary technology.
The collaboration aims to combine Rocketvax's innovative vaccine development with Emergent's production capabilities, supporting Emergent's strategic focus on growth and transformation while advancing breakthrough medical technologies.
Emergent BioSolutions (NYSE:EBS) has announced the sale of its Baltimore-Bayview drug substance manufacturing facility to Syngene International for $36.5 million. The facility includes manufacturing, laboratory, warehousing and office space, equipped with multiple monoclonal antibody manufacturing lines.
As part of the agreement, Emergent will maintain rights to secure manufacturing services and capacity at the facility for future growth and pandemic response production. The company will continue operating facilities in Lansing, Michigan and Winnipeg, Manitoba.
The sale, expected to close in Q1 2025, aligns with Emergent's multi-year transformation plan. Notably, the Bayview site received a 'No Action Indicated' (NAI) status from the FDA in March 2024, indicating favorable inspection outcomes.
Emergent BioSolutions (EBS) reported Q4 2024 financial results with total revenues of $194.7 million and full-year revenues of $1.04 billion. The company posted a Q4 net loss of $31.3 million, representing a 37% improvement from the previous year. Q4 Adjusted EBITDA reached $21.0 million, a 518% increase year-over-year.
Key Q4 performance metrics showed mixed results across segments:
- NARCAN® sales decreased 41% due to lower OTC and Canadian retail sales
- Anthrax MCM products declined 71%
- Smallpox MCM products surged 565%
- Commercial Products segment gross margin fell 57% to $22.4 million
The company completed several strategic initiatives in 2024, including receiving $550 million in Medical Countermeasure Contract awards, repaying $168 million of debt, and completing $117 million in asset divestitures. For 2025, Emergent is guiding Adjusted EBITDA of $150-200 million with improved gross margins.
Emergent BioSolutions (NYSE: EBS) has announced two upcoming investor events. The company will host a conference call on March 3, 2025, at 5:00 pm ET to discuss fourth quarter and full year 2024 financial results. Additionally, company leaders will present at J.P. Morgan's 2025 Leveraged Finance Conference on February 24, 2025, at 11:00 am ET.
Both events will be accessible via webcast through the company's Investors page. For the earnings call, telephone participants must register in advance to receive dial-in details and access credentials. A replay of the earnings call will be available on Emergent's website.
Emergent BioSolutions (NYSE: EBS) is partnering with pro football legend Emmitt Smith to raise awareness of the Ready to Rescue initiative in New Orleans during the Big Game weekend. The campaign focuses on opioid overdose prevention and the use of NARCAN® Nasal Spray.
Despite a national decline in opioid overdose deaths reported by the CDC, New Orleans continues to face increasing drug-related deaths. In 2022, drug-related overdose deaths were nearly double the number of homicides in the city. The campaign features Smith in a 'Lay, Spray, Stay' educational video demonstrating NARCAN® administration, which will be displayed on local taxi television screens throughout the city.
The initiative coincides with New Orleans hosting approximately 83,000 fans for the Big Game. Hundreds of NARCAN® Nasal Spray cartons will be distributed in the city during the weekend. The campaign aims to reduce stigma around accidental opioid poisonings and educate communities on life-saving interventions.
Africa CDC has initiated patient enrollment in the MOSA trial, a pan-African randomized platform adaptive study for Mpox treatment at Mbandaka Hospital in DRC. The study, primarily evaluating brincidofovir, comes as Mpox remains a significant health threat across Africa, particularly affecting vulnerable populations.
The trial follows recent studies (PALM 007 and STOMP) showing tecovirimat's effectiveness in lesion resolution. MOSA will assess different antivirals' safety and efficacy, starting with brincidofovir, an antiviral from Emergent BioSolutions currently available in the US under emergency use IND for Mpox.
The study protocol includes a two-week treatment period with either brincidofovir or placebo in liquid oral form, administered weekly. The first interim analysis is expected by Q1 2025. The trial, sponsored by PANTHER and initially funded by EU's Horizon Europe program, will recruit both children and adults, focusing on those at highest risk of severe outcomes.
Emergent BioSolutions (NYSE: EBS) has secured exclusive commercial rights to KLOXXADO® (naloxone HCl) Nasal Spray in the U.S. and Canada from Hikma Pharmaceuticals through a six-year agreement. This 8 mg naloxone product complements EBS's existing NARCAN® Nasal Spray 4 mg, expanding their portfolio of opioid overdose emergency treatments.
The agreement comes as CDC reports the first meaningful decline in U.S. opioid overdose deaths since 2018. NARCAN® will continue to be available over-the-counter as a 4 mg standard treatment, while KLOXXADO®'s 8 mg dosage will be available by prescription for those requiring higher doses.
Hikma will continue manufacturing KLOXXADO®, which will be integrated into Emergent's NARCANDirect™ online distribution network. This platform serves qualified direct purchasers including emergency services, law enforcement, government agencies, and community-based programs.
Emergent BioSolutions (NYSE: EBS) has received a $16.7 million contract option from BARDA to continue development of Ebanga™, a treatment for Zaire Ebola virus infection. This modification represents the second option period of their existing 10-year contract, which has a maximum value of $704 million.
The contract includes a base period and two option periods for advanced development valued at $118 million, plus additional option periods for Ebanga™ procurement worth up to $583 million. Under the contract terms, Emergent will focus on drug product process validation, analytical testing validation, and long-term stability studies. The company will also work on manufacturing scale-up, technology transfer, and completing stability studies, culminating in a supplemental Biologics License Application to the FDA.
Emergent BioSolutions (NYSE: EBS), a public health company focused on protective and life-saving solutions, has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference. Joe C. Papa, the company's president and CEO, will deliver a presentation on Wednesday, January 15, 2025, at 1:30 PM PST.
The presentation will be accessible through an audio link, which will remain available for 30 days following the event. Additionally, the presentation slides will be published in the Investors section of Emergent's website coinciding with the presentation time.
FAQ
What is the current stock price of Emergent Biosolutions (EBS)?
What is the market cap of Emergent Biosolutions (EBS)?
